Table 5.
TCGA study cohort: patient and pathologic characteristics of recurrent and non-recurrent ECs.
| All Cases n = 548 |
Recurrent ECs n = 124 |
Non-Recurrent ECs n = 424 |
p Value | |
|---|---|---|---|---|
| Mean age, years (± SD) | 63.9 ± 11.1 | 64.6 ± 9.7 | 63.7 ± 11.5 | 0.37 |
| Mean BMI (± SD) | 33.8 ± 12.1 | 33.2 ± 8.4 | 34 ± 12.9 | 0.53 |
| Surgical approach | ||||
| Minimally invasive | 203(37) | 55(44.4) | 148(34.9) | 0.04 |
| Laparotomy | 321(58.6) | 63(50.8) | 258(60.8) | |
| N/A | 24(4.4) | 6(4.8) | 18(4.2) | |
| ProMisE classification | ||||
| POLE | 65(17.3) | 3(3.8) | 62(20.9) | <0.001 |
| MMRd | 110(29.3) | 24(30.8) | 85(29) | |
| p53abn | 54(14.4) | 22(28.2) | 32(10.8) | |
| NSMP | 146(38.9) | 29(37.2) | 117(39.4) | |
| Histology | ||||
| Endometrioid | 411(75) | 74(59.7) | 337(79.5) | <0.001 |
| Mixed serous and endometrioid | 22(4) | 8(6.5) | 14(3.3) | |
| Serous endometrial adenocarcinoma | 115(21) | 42(33.9) | 73(17.2) | |
| FIGO Stage | ||||
| I | 245(65.3) | 37(47.4) | 208(70) | <0.001 |
| II | 32(8.5) | 3(3.8) | 29(9.8) | |
| III | 82(21.9) | 26(33.3) | 56(18.9) | |
| IV | 16(4.3) | 12(15.4) | 4(1.3) | |
| Grade | ||||
| G1 | 99(18.1) | 10(8.1) | 89(21) | <0.001 |
| G2 | 122(22.3) | 21(16.9) | 101(23.8) | |
| G3 | 327(58.9) | 93(75) | 234(55.2) |
BMI: body mass index; EC: endometrial cancer; FIGO: International Federation of Gynaecology and Obstetrics; G: grade; MMRd: mismatch repair deficiency; NA: not available; NSMP: no specific molecular profile; ProMisE: Proactive Molecular Risk Classifier for Endometrial Cancer; TCGA: The Cancer Genome Atlas. Bold highlights the statistical significance.